{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-21-000023","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.011937+00:00","generated_at":"2026-06-29T22:09:33.465920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B","bullets":["Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.","GAAP diluted EPS $27.97 vs $7.61 in Q2 2020; non-GAAP diluted EPS $25.80 vs $7.16.","EYLEA US net sales record $1.42B (+28% YoY); Dupixent global net sales $1.50B (+59% YoY, recorded by Sanofi).","REGEN-COV: $2.59B US sales from 1.25M doses; EUA expanded for prophylaxis; Japan full approval; RECOVERY trial showed 20% mortality reduction in seronegative.","Pipeline: Dupixent Phase 3 CSU positive; Libtayo Phase 3 NSCLC stopped early for survival benefit; $1.8B Tarrytown campus expansion over 6 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-21-000023","json":"https://secwatch.observer/filing/0001804220-21-000023.json","markdown":"https://secwatch.observer/filing/0001804220-21-000023.md","text":"https://secwatch.observer/filing/0001804220-21-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/0001804220-21-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/regn-20210805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:09:33.465920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}